Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07070830 · ClinicalTrials.gov registry record · NA
Simplified Onboarding in Adults With Type 2 Diabetes
A NA study, sponsored by Insulet Corporation.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT07070830: Completed NA study, sponsored by Insulet Corporation.
NCT07070830 is a NA study that has completed, run by Insulet Corporation. The registered enrollment target is 56 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07070830, a NA study, has completed, sponsored by Insulet Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is an outpatient study testing different starting doses of insulin in participants with type 2 diabetes. Participants will manage their diabetes using the Omnipod M System. The system is comprised of an Omnipod M Pod, an Omnipod M Controller, and will be used with a Dexcom G6 continuous glucose monitoring sensor (CGM). The main objectives of the study are to evaluate the safety and tolerability of different starting doses of insulin using the Omnipod M System. There is a precursory evaluation before the main, randomized trial. Participation in the precursory evaluation could last up to 12 weeks and participation in the randomized trial could last up to 6 weeks. During both the evaluation and the randomized trial, participants will manage their diabetes using the Omnipod M System in Automated Mode. An optional 12-weeks of continued Omnipod M System use is available upon completion of the randomized trial.
Primary Outcome
Glucose metric from study continuous glucose monitoring system
Interventions
- DEVICE Active Comparator: Omnipod M System with lower starting dose
- DEVICE Active Comparator: Omnipod M System with higher starting dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2026-01-06 |
| Phase | NA |
What the finished NCT07070830 record still lists
NCT07070830 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Active Comparator: Omnipod M System with lower starting dose is the first listed.
NCT07070830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07070830 about?
NCT07070830 is a clinical study titled "Simplified Onboarding in Adults With Type 2 Diabetes". This is an outpatient study testing different starting doses of insulin in participants with type 2 diabetes. Participants will manage their diabetes using the Omnipod M System. The system is comprised of an Omnipod M Pod, an Omnipod M Controller, and will be used with a Dexcom G6 continuous glucose...
What is the current status of trial NCT07070830?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2025-07-18. Estimated completion is 2026-01-06.
What interventions are being tested in trial NCT07070830?
The interventions under investigation include: Active Comparator: Omnipod M System with lower starting dose (DEVICE), Active Comparator: Omnipod M System with higher starting dose (DEVICE).
Who is sponsoring clinical trial NCT07070830?
This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07070830's enrollment target sits among peer trials
56 1262nd of 2000 higher than 737 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI